Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 2 of 2 results for ganciclovir

  1. Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)

    Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.

    Technology appraisal guidance
    Published
    18 January 2023
    View recommendations

    Sections for TA860

  2. Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)

    Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus disease after a stem cell transplant.

    Technology appraisal guidance
    Published
    31 July 2019
    View recommendations

    Sections for TA591